Skip to main content

Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis



Advanced pulmonary sarcoidosis causes significant morbidity and can lead to death. Large trials demonstrated efficacy of antifibrotics in patients with progressive fibrosing interstitial lung diseases (PF-ILD), including a few with sarcoidosis. To date, little is known about this progressive fibrosing phenotype in sarcoidosis. Diffusion capacity of carbon monoxide (DLCO) may be a useful functional marker to screen for advanced pulmonary sarcoidosis. In this study, we describe a cohort with advanced pulmonary sarcoidosis and we gain insights in the progressive fibrosing phenotype in sarcoidosis.


Patients with sarcoidosis and a DLCO < 50% predicted were included in this retrospective cohort study. First measurement of DLCO < 50% predicted was the baseline. Lung function data, HRCT, pulmonary hypertension (PH) and mortality were collected. Patients with > 10% fibrosis on HRCT meeting the criteria for ILD-progression within 24 months were labelled as PF-ILD. With Cox-regression analysis predictors of mortality were established.


106 patients with a DLCO < 50% predicted were included. Evolution of forced vital capacity (FVC) varied widely between patients from − 34% to + 45% after 2 years follow-up, whereas change in DLCO varied between − 11% and + 26%. Fourteen patients (15%) met the PF-ILD criteria, of whom 6 (43%) died within 10 years versus 10 (13%) in the non PF-ILD group (p = 0.006). PH was present 12 (11%), 56 (53%) demonstrated > 10% fibrosis on HRCT. Independent predictors of mortality and lung transplantation in the whole cohort are PH, PF-ILD and UIP-like pattern.


In conclusion, within this group with advanced pulmonary sarcoidosis disease course varied widely from great functional improvement to death. PF-ILD patients had higher mortality rate than the mortality in the overall pulmonary sarcoidosis group. Future research should focus on the addition of antifibrotics in these patients.

Trial registration retrospectively registered


Sarcoidosis is a multi-organ granulomatous disorder characterized by a wide variety of clinical phenotypes [1]. About one third of patients with sarcoidosis develop a chronic course of disease [2]. Chronic pulmonary sarcoidosis can cause significant morbidity due to progressive fibrosis, pulmonary hypertension (PH), aspergilloma or other respiratory infections. Strikingly, several studies demonstrated that death rate of sarcoidosis has increased over the last decades [3, 4]. Respiratory insufficiency is the main cause of death of sarcoidosis in the western world [4, 5]. Advanced age, extensive fibrosis on high-resolution computed tomography (HRCT) and the presence of PH have been identified as predictors of mortality in sarcoidosis [6, 7].

Recently, the INBUILD trial revealed that nintedanib slowed disease progression in a heterogeneous group of patients with progressive fibrosing interstitial lung diseases (PF-ILD). The majority of patients consisted of patients with fibrotic hypersensitivity pneumonitis (fHP) and connective tissue disease (CTD)-ILD. This large randomized controlled trial also included several patients with sarcoidosis [8]. The outcomes of the INBUILD trial therefore suggests that treatment with antifibrotic therapy might potentially be useful in patients with sarcoidosis who meet the criteria for PF-ILD. However, nintedanib can cause significant side effects and is relatively expensive and therefore patients to be treated are ideally carefully selected. To date, it is unknown how many patients with sarcoidosis actually meet the criteria for PF-ILD.

The different clinical phenotypes in sarcoidosis make it difficult to predict its course. Walsh and colleagues developed a clinico-radiological risk-stratification system to identify patients with sarcoidosis at risk. This composite score included the following variables: CPI (composite physiological index), main pulmonary artery diameter to ascending aorta diameter ratio (MPAD/AAD ratio) and presence of more than 20% fibrosis on the HRCT [9]. As the authors mention in their paper, the prognostic strength of the CPI might be the incorporation of diffusion capacity (DLCO) to capture increased sensitivity to PH as well as the prognostic effect of DLCO in interstitial lung disease [9]. Given the somewhat laborious formula, the CPI is hardly used in daily practice whereas the DLCO is an integral part of pulmonary function testing in ILD. The combination of prognostic strength as well as overall availability should make the DLCO a useful tool in screening for advanced sarcoidosis [10]. DLCO negatively correlates with saturation during exercise in patients with ILD [11]. In addition, in patients with a diffusion capacity less than 50% a desaturation of 4% or more was found during exercise [11]. This change in saturation might have a great impact on experiencing dyspnea during exercise. For these reasons, we chose DLCO < 50% as entry criteria for selecting patients with advanced pulmonary sarcoidosis.

The aim of this paper is to describe functional and radiological characteristics and prognosis of a cohort with patients with advanced pulmonary sarcoidosis defined by severely limited DLCO. We investigated how many patients with advanced pulmonary sarcoidosis meet the criteria for PF-ILD and the prognosis of this subgroup.


In this retrospective study cohort, we included 106 patients with sarcoidosis with at least at one time point a DLCOc of less than 50% of predicted. All patients with sarcoidosis with a DLCOc < 50% of predicted and with an HRCT at the baseline ± 1 year at St. Antonius Hospital Nieuwegein, the Netherlands between 1996 and 2018 were selected. The first time point at which the DLCOc was < 50% of predicted in our hospital since the diagnosis sarcoidosis was defined as baseline. Sarcoidosis was diagnosed according to the guidelines of ERS/ATS/WASOG [12].

At the baseline the following data were collected: the lung function, Scadding stage, organ involvement, HRCT data and treatment. Follow-up lung function data were collected 1 year and 2 years after the baseline. The following data were also collected: date of diagnosis, date of birth, sex and ethnicity. Research related lab work (e.g., MUC5B) was performed retrospectively from the ILD biobank. Figure 1 pictures the study timeline.

Fig. 1
figure 1

Study timeline. DLCOc = diffusion capacity for carbon monoxide corrected for haemoglobin; PF-ILD = progressive fibrosing interstitial lung disease. *The phenotype PF-ILD was established when the following conditions were met: > 10% fibrosis on the HRCT and progressive disease within 24 months of the baseline: a relative decline of FVC of 10% of predicted, a relative decline of FVC of 5–10% of predicted in combination with an increase of fibrosis or worsening of respiratory symptoms, or an increase of fibrosis on HRCT in combination with worsening of respiratory symptoms

The composite score of Walsh was determined as described in the paper of Walsh et al. [9], and divides the population in patients with a good and poor prognosis. Patients with a CPI higher than 40 were classified as patients with poor prognosis. Patients with CPI ≤ 40, but a MPAD/AAD > 1 or extent of fibrosis > 20% were also classified as patients with a poor prognosis [9].

The survival period was calculated from baseline to the date of death or lung transplantation, or in the case of survivors to the last known contact. The mortality rate was calculated after 5 and after 10 years. Information concerning vital status of the patient and the cause of death was obtained from patient files or from the general practitioner. Transplant-free survival was defined as survival free of lung-transplantation or death. The study was approved by the Medical research Ethics Committees United (MEC-U) of the St. Antonius Hospital (R05-08A) and all subjects gave written informed consent.

Lung function

The following lung function parameters were collected: forced vital capacity (FVC), forced expiratory volume in one second (FEV1), diffusion capacity for carbon monoxide corrected for haemoglobin (DLCOc). Finger-prick blood samples were used to estimate venous haemoglobin (Hb) prior to pulmonary function testing. The pulmonary function data were expressed in litres and as percentage of predicted (% pred.). Lung function data were collected from the moment of the first measurement of DLCOc < 50% of predicted (baseline) and after 2 years ± 3 months. In patients with PF-ILD we collected lung function data 1 year after the diagnosis PF-ILD. CPI at baseline was calculated as previously described by Wells and colleagues [13]: CPI = 91.0 − (0.65 × DLCO % of predicted) − (0.53 × FVC % of predicted) + (0.34 × FEV1% of predicted).

High resolution computed tomography

High-resolution computed tomography (HRCT) was available in all patients at baseline ± 1 year, missing data were handled with pairwise deletion.

A thoracic radiologist with special expertise in ILD (DM) reviewed all HRCT’s according to the staging system described by Walsh et al. [9]. In short, the lungs were assessed for the extent of fibrosis, reticulation with or without honeycombing, groundglass and other patterns of disease (not defined as fibrosis or groundglass). The proportion of the total disease extent and the above mentioned three individual patterns were estimated to the nearest 5%. The radiologist described the absence or presence of traction bronchiectasis and emphysema.

Furthermore, the ratio between the diameter of the mean pulmonary artery and the diameter of the ascending aorta (MPAd/AAd ratio) was measured and subdivided into three categories [9]: (0) diameter of pulmonary trunk less than diameter of ascending aorta; (1) pulmonary trunk diameter/ascending aorta dimeter ratio greater than 1 but less than or equal to 1.25; (2) pulmonary trunk diameter/ascending aorta diameter ratio greater than 1.25.

In addition, HRCTs were screened for UIP-like (usual interstitial pneumonia like) pattern as described in the INPULSIS trial [14]. Because the inter-observer agreement for the criteria for UIP is moderate [15], two radiologists screened on a UIP-like pattern. In cases of disagreement a third radiologist made the consensus decision on the presence of UIP-like pattern. A UIP-like pattern was noted if a patient met criteria A and C, B and C or all three criteria A, B and C:

  1. A.

    Definite honeycomb destruction with basal and peripheral predominance

  2. B.

    Presence of reticular abnormality and traction bronchiectasis

  3. C.

    Atypical features are absent, specifically nodules and consolidation. Ground glass opacity, if present, is less extensive than reticular pattern.


Mucin 5B (MUC5B) promotor polymorphism was analysed as described before in the paper of van der Vis and colleagues [16]. In short, genomic deoxyribonucleic acid was extracted from peripheral blood of each individual using standard method. A pre‐designed taqman single nucleotide polymorphism genotyping assay and an ABI 7500Fast analyzer (Applied Biosystems, Foster City, CA) were used to genotype rs35705950. We compared the minor allele frequency of the patients of our cohort with the minor allele frequency of healthy control subjects. In the healthy control group 249 healthy unrelated Dutch Caucasians were included.


PF-ILD was defined as described in the INBUILD trial [8]. All patients with PF-ILD had more than 10% fibrosis on the HRCT. The disease was defined as progressive if the following criteria were met within 24 months of the baseline: a relative decline of FVC of 10% of the predicted value, a relative decline of FVC of 5–10% of the predicted value in combination with an increase of fibrosis or worsening of respiratory symptoms, or an increase of fibrosis on HRCT in combination with worsening of respiratory symptoms. Patients with incidental decrease of FVC (thus only one measurement of FVC loss followed by an increase of FVC) were not labelled as progressive disease. Our thoracic radiologist (DM) evaluated the HRCT for progression of fibrosis.

We collected the follow-up of lung function data from the moment that a patient met the criteria for PF-ILD was until 1 year thereafter. We have chosen the same follow-up duration of 1 year as was described in the large INBUILD trial.


Statistical analyses were performed using IBM SPSS version 24 and Graphpad prism software version 6.05. Continuous variables are expressed as mean ± standard deviation (parametric data) or median with interquartile range (non-parametric data). Differences between groups with continuous data were tested with student-t test or the Mann–Whitney U test where appropriate. Numeric data are expressed as number (percentage), and differences between non-continuous data were measures with chi-square test. Survival analysis was performed using the Kaplan–Meier curves. For the composite endpoint overall mortality patients who underwent lung transplantation were considered dead. Univariate Cox regression analysis was used to identify predictors for transplant-free survival. Subsequently, we used multivariate Cox regression analysis in order to demonstrate independent predictors of transplant-free survival. Candidate covariates from the univariate analysis were included for multivariate analysis if p < 0.05. No missing data substitutions were made. Missing data were handled with pairwise deletion.


The cohort consisted of 106 patients with advanced pulmonary sarcoidosis. The patient characteristics at baseline are outlined in Table 1. The mean age of this study cohort was 49 years and 68% of the patients were male. Median duration of disease prior to the first measurement of DLCO < 50% of predicted was 5 years. Mean CPI was 47 ± 9, and a CPI above 40 was measured in 87 patients. According to the algorithm of Walsh 98 patients (92%) of the patients are suspected to have a poor prognosis: 87 out of the 98 patients (89%) had a CPI above 40, 8 out of the 98 patients (8%) had more than 20% fibrosis on HRCT and 8 out of the 98 patients (8%) had a MPAd/AAd ratio of more than 1.

Table 1 Patient characteristics at first measurement of DLCO < 50% of predicted

In addition, at baseline, 12 patients (11%) were diagnosed with PH based on mPAP > 25 mmHg during right heart catheterisation (n = 9) or compatible findings of transthoracic echocardiography (n = 3). The diagnosis of PH using echocardiography was based on a high tricuspid regurgitation maximum velocity of 4.4 m/s and secondary signs of pulmonary hypertension in one patient and in two patients based on secondary signs of pulmonary hypertension, such as right atrial dilatation, hypertrophy of right ventricle and paradoxical septal motion. In the patients who received right heart catheterisation mPAP (mean pulmonary arterial pressure) was 38 ± 13 mmHg. 76 patients (72%) were treated with immunosuppressive therapy at the baseline.

The minor allele frequency for MUC5B rs35705950 in our cohort was 11% and did not significantly differ from the minor allele frequency of 9% in the controls (p > 0.05).

Change in lung function

Mean FVC at baseline was 70% of predicted and mean DLCO at baseline was 42% of predicted (Table 1).

After 2 years, four patients had died (4%) and FVC and DLCO were available for 59 and 51 patients, respectively. Evolution of lung function varied widely between patients. Change in FVC after 2 years follow-up ranged between − 34% and + 45% of predicted, whereas change in DLCO varied between − 11% and + 26%.

After 2 years of follow-up 29 patients (46%) of the patients had improved FVC and 12 patients (22%) improved DLCOc (Fig. 2). Deterioration of FVC was in 10 (16%) of the patients, whereas only 2 (4%) had deterioration of DLCOc (Fig. 2).

Fig. 2
figure 2

Proportions of patients with improved, stable or deteriorated lung function and patients who died. A improvement, stable or deteriorated FVC after 2 years; B improvement, stable or deteriorated DLCOc after 2 years. FVC: Improvement ≥ + 5% predicted; Stable − 5 to + 5% predicted; deterioration ≥ − 5% predicted. DLCOc: Improvement ≥ + 10% predicted; stable − 10 to + 10% predicted; deterioration ≥ − 10% predicted


HRCT data at baseline ± 1 year were available in 106 patients (Table 2). In this cohort, the median total disease extent of the lung was 70%. The most prominent HRCT pattern was groundglass, with a median of 21% involvement of the lungs. A total of 56 patients had more than 10% fibrosis on HRCT. Furthermore, only four (4%) patients had a UIP-like pattern on HRCT.

Table 2 HRCT characteristics at baseline in patients with a HRCT at baseline


In 94 patients we had enough data to apply the criteria for PF-ILD as used in the INBUILD trial. We found that 14 out of the 94 patients (15%) met the PF-ILD criteria.

Lung function data after 1 year from the moment that patients had PF-ILD showed no significant increase or decrease (Fig. 3). In two patients follow-up lung function data were not available because they had already died. All patients received immunosuppressive therapy at the time they met the criteria of PF-ILD. Three patients switched immunosuppressive therapy within 1 year of follow-up.

Fig. 3
figure 3

One year follow-up FVC (% of predicted) in patients with PF-ILD. Time 0 (T = 0) is the first time that patients fulfil the criteria for PF-ILD. No difference was found between survivors and non-survivors in change in FVC after 1 year follow-up in patients with PF-ILD (p > 0.05)

Patients with PF-ILD are characterized by more fibrosis and traction bronchiectasis on HRCT (Table 3). Mortality in the PF-ILD group was significantly higher than in the non PF-ILD group (43% versus 13%; p = 0.013). One patient underwent a bilateral lung transplantation, 3 patients died because of end-stage fibrotic sarcoidosis and two patients died because of pneumonia in the PF-ILD group. There was no significant difference in MUC5B rs35705950 T-allele carriership between PF-ILD and non PF-ILD. However in the whole cohort (PF-ILD and non PF-ILD) three out of four patients with UIP pattern on HRCT carried the MUC5B T-allele.

Table 3 Characteristics of patients with PF-ILD versus non PF-ILD at baseline (DLCO < 50% of pred.)


Univariate analysis

A total of 15 patients died of whom in 14 patients it was definitely attributable to sarcoidosis. In one patient the cause of death was familial dilated cardiomyopathy (not sarcoidosis related). Three patients underwent bilateral lung transplantation, and four patients died on the waiting list.

In the total cohort, the 5- and 10-year overall mortality was 11% and 16%, respectively.

Univariate Cox regression analysis revealed four predictors for the composite endpoint of overall mortality (Table 4): CPI (HR 1.1; 95% CI 1.0–1.1; p = 0.049), PH (HR 3.8; 95% CI 1.0–14.3; p = 0.047), PF-ILD (HR 4.5; 95% CI 1.6–12.5; p = 0.004), and a UIP-like pattern on HRCT (HR 9.8; 95% CI 2.6–36.6; p = 0.001).

Table 4 Univariate and multivariate analysis of predictors of mortality and lung transplantation

Multivariate analysis

The following covariates were analysed with multivariate Cox regression analysis: CPI, PH, PF-ILD and UIP-like pattern. Multivariate Cox regression analysis demonstrated that three covariates are independent predictors of overall mortality and lung transplantation: PH, PF-ILD and UIP-like pattern (Table 4). Comparison of transplant-free survival in patients with and without PF-ILD is shown by Kaplan Meier curve in Fig. 4A and with and without PH in Fig. 4B.

Fig. 4
figure 4

Kaplan Meier curves for the transplant-free survival. A Survival analysis in patients with and without PF-ILD; B survival analysis in patients with and without PH. Median survival patient with PF-ILD = 6 years; median survival patients with PH = 5 years


In this study in patients with advanced pulmonary sarcoidosis based on a severely impaired diffusion capacity, we demonstrated that 15% of patients meet the current criteria for progressive fibrosing ILD (PF-ILD). In our study cohort, we found PH, PF-ILD and UIP-like pattern on HRCT to be independent predictors for all-cause mortality and lung transplantation. In the group of sarcoidosis who meet PF-ILD criteria, 43% died or underwent bilateral lung transplantation, whereas the overall mortality in the non-PF-ILD was 13%.

As no well-described definition of advanced pulmonary sarcoidosis exists, we chose to use DLCO as determining criterion. DLCO is reduced in 90% of the patients with advanced pulmonary sarcoidosis [17]. Furthermore, in the absence of fibrosis DLCO might be limited in patients with sarcoidosis, for example in patients with PH [18]. An important observation in our study is the significant heterogeneity in disease course. Although a severely impaired diffusion capacity in patients with IPF or CTD-ILD in general is associated with a poor prognosis [19], we see a remarkably high percentage of patients in our study cohort where FVC remains stable (32%) or even improved (46%) after 2 years of follow-up. One explanation could be that patients with sarcoidosis generally respond well to immunosuppressive therapy. In the observational multi-center study of Kampstra et al. (20) including 509 patients with different stages of sarcoidosis was found that 21% of the patients had an improvement of FVC and 17% had an improvement of DLCO after 2 years follow-up. The mean % of DLCO in our study cohort was 42% which is comparable with mean DLCO at baseline in, for example, the ASCEND, INPULSIS and INBUILD trial, 44%, 47% and 46% respectively [8, 21, 22].

We demonstrated that PF-ILD is rare, even in patients with advanced pulmonary sarcoidosis, as our data show that only 15% of our cohort fulfil the criteria of PF-ILD. In the overall sarcoidosis-population, the percentage of patients fulfilling the criteria of PF-ILD would be significantly lower because we used an inclusion criterion of at least one measurement of DLCOc < 50% predicted. A retrospective Italian study found that 41% of sarcoidosis patients with Scadding stage IV had PF-ILD, which is much higher than the prevalence what we found. This difference might be explained by the fact that in our study PF-ILD was diagnosed if patients had more than 10% fibrosis on HRCT and met the criteria for progressive disease according to the INBUIDL trial, whereas in the Italian study patients with Scadding stage IV who met the criteria for progressive disease were labelled as PF-ILD [23].

In the patients with PF-ILD we found a mean increase of 105 mL FVC after 1 year follow-up (data not shown), whereas in the placebo-group of the INBUILD trial a mean decrease of -187.8 mL after 1 year was found. However, our data cannot be compared with the outcomes of the INBUILD trial, because in the INBUILD trial tipping point analysis is used to impute FVC data in patients who died. Despite stable FVC after 1 year follow-up in patients with PF-ILD, our data also demonstrate that PF-ILD in patients with advanced pulmonary sarcoidosis is associated with a poor prognosis given the fact 43% of this group died from sarcoidosis related causes. From these findings, we might conclude that FVC does not give a realistic reflection of the severity of the disease. However, our lung function results should be interpreted with caution as the group composed only 14 patients. In the study of Behr and colleagues [24], describing the course of disease in IPF patients with and without antifibrotic therapy, was demonstrated that overall decline of FVC did not differ between patients with and without antifibrotic therapy, whereas they found a great significant difference in mortality between patients with and without antifibrotic therapy. CPI (incorporating FVC, FEV1 and DLCO) or 6-min walk test (6MWT) seem more suitable as clinical parameters to evaluate the therapeutic effect in sarcoidosis, as both parameters are clinical predictors of mortality in ILD [9, 25]. In the INBUILD trial, patients did not receive other therapy besides nintedanib or placebo, whereas in our cohort all patients with PF-ILD received immune suppressive treatment.

Nintedanib is not a curative treatment, and a relatively expensive drug [26] and can have substantial side-effects, and therefore patients and society can benefit from careful selection prior to initiation of this therapy. In the light of the recently published INBUILD trial, we suggest that patients with advanced pulmonary sarcoidosis fulfilling the criteria for PF-ILD might benefit from treatment with nintedanib.

Although the vast majority of the total cohort remained stable or even improved in terms of lung function, 12 patients (11%) eventually died or received lung transplantation within 5 years. Presence of PF-ILD, UIP-like pattern on HRCT and presence of PH were independent predictors of mortality. Unlike the findings in the United States and France [4, 6], we were not able to demonstrate racial or sex differences in mortality. However, this might be because the limited power of this study for mortality. Only a few studies focused on mortality in advanced pulmonary sarcoidosis [5, 6]. The overall 5-year mortality including lung transplantation was 11% in our study, which is similar to the results of Nardi and colleagues a 5-years mortality rate of 8.5% and that 4% underwent a lung transplantation [5] in a cohort with patients with only Scadding stage IV. Four out of six patients waiting for lung transplantation died. In a retrospective study, investigating mortality in patients with sarcoidosis on the transplant wait list, 18% died within 1 year and DLCO was found to be a strong predictor for death [27]. This study in combination with our results underlines the importance of appropriate timing for referral for lung transplantation.

Although 56 patients had more than 10% fibrosis on HRCT, a UIP-like pattern was found in only four patients. A UIP-like pattern is rare in sarcoidosis, therefore the question remains if patients with a UIP pattern in sarcoidosis might have two disorders or that a UIP pattern is a rare consequence of progressive fibrosis in sarcoidosis. The continuous inflammatory condition of the lungs may predispose to the development of a UIP in susceptible patients with sarcoidosis. In addition, pro-fibrotic genetic markers can play a role in the development of a UIP pattern in sarcoidosis. Three out of four patients with a UIP on HRCT carried the MUC5B T-allele. In RA-ILD it was shown that UIP is associated with presence of the MUC5B T-allele [28]. A similar situation may be present in sarcoidosis although UIP is much less frequent and subsequent studies focussing on this rare phenotype in sarcoidosis are needed to confirm this hypothesis. Thus far, only one other study has investigated the association between MUC5B variant and sarcoidosis. Stock et al. [29] demonstrated that MUC5B is not associated with fibrotic sarcoidosis (Scadding stage IV) nor with progression of sarcoidosis. However, they did not study the association between the presence of the UIP pattern in fibrotic sarcoidosis and MUC5B genotype.

The last independent predictor found for overall mortality was the presence of PH. It is well known that PH is associated with a poor prognosis in sarcoidosis [5,6,7]. In our cohort with advanced pulmonary sarcoidosis, 11% of the patients had PH at baseline. The incidence of PH in the overall sarcoidosis population varies widely from 3 to 20% [30,31,32,33,34], and in patients awaiting for lung transplantation the incidence is even higher varying from 39% up to 79% [27, 35]. In 58% of the patients with PH, fibrosis was found on HRCT. This is in line the study of Sulica et al. [36], this retrospective study found that 60% of the patients with PH had fibrosis.

As our study is retrospective, lung function and HRCT were not performed at strictly set times, and therefore we had some missing data. However, the aim of our study was to describe a cohort with advanced pulmonary sarcoidosis and we feel that our cohort is a realistic reflection of this phenotype in clinical practice.


In conclusion, in this study on advanced pulmonary sarcoidosis defined on the basis of severely lowered DLCO (< 50%), a PF-ILD phenotype was found in 15%. Overall disease course showed remarkable heterogeneity. Although lung function in most patients improved or stabilised, overall 5-year and 10-year mortality in the whole cohort was substantial with 11% and 16%, respectively. Independent negative predictors of transplant-free survival were PH, UIP-like pattern and PF-ILD phenotype. Future research should focus on the efficacy and timing of antifibrotic therapy in patients with sarcoidosis with a PF-ILD phenotype.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.


95% CI:

95% Confidence interval


Composite physiological index


Connective tissue disease


Diffusion capacity of carbon monoxide


Forced expiratory volume in one second


Forced vital capacity


Hazard ratio


High-resolution computed tomography


Hypersensitivity pneumonitis


Idiopathic pulmonary fibrosis


Mean pulmonary artery diameter/ascending aorta diameter


Mean pulmonary arterial pressure




Progressing fibrotic interstitial lung disease


Pulmonary hypertension


Right heart catheterization


Usual interstitial pneumonia


  1. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis [Internet]. N Engl J Med. 2007;357:2153.

    CAS  Article  Google Scholar 

  2. Rubio-Rivas M, Corbella X. Clinical phenotypes and prediction of chronicity in sarcoidosis using cluster analysis in a prospective cohort of 694 patients. Eur J Intern Med [Internet]. 2020;77:59.

    Article  Google Scholar 

  3. Swigris JJ, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger D, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med [Internet]. 2011;183(11):1524–30.

    Article  Google Scholar 

  4. Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. Chest. 2015;147(2):438–49.

    Article  Google Scholar 

  5. Nardi A, Brillet PY, Letoumelin P, Girard F, Brauner M, Uzunhan Y, et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J [Internet]. 2011;38(6):1368–73.

    CAS  Article  Google Scholar 

  6. Jeny F, Uzunhan Y, Lacroix M, Gille T, Brillet PY, Nardi A, et al. Predictors of mortality in fibrosing pulmonary sarcoidosis. Respir Med [Internet]. 2020;169.

  7. Kirkil G, Lower EE, Baughman RP. Predictors of mortality in pulmonary sarcoidosis. Chest [Internet]. 2018;153(1):105–13.

    Article  Google Scholar 

  8. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med [Internet]. 2019;381(18):1718–27.

    CAS  Article  Google Scholar 

  9. Walsh SLF, Wells AU, Sverzellati N, Keir GJ, Calandriello L, Antoniou KM, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med [Internet]. 2014;2(2):123–30.

    Article  Google Scholar 

  10. Boros PW, Enright PL, Quanjer PH, Borsboom GJJM, Wesolowski SP, Hyatt RE. Impaired lung compliance and DL, CO but no restrictive ventilatory defect in sarcoidosis. Eur Respir J [Internet]. 2010;36(6):1315–22.

    CAS  Article  Google Scholar 

  11. Kelley MA, Panettieri RA, Krupinski A V, Philadelphia R. Resting Single-Breath Diffusing Capacity as a Screening Test for Exercise-Induced Hypoxemia. 1986.

  12. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis, Vasc Diffus lung Dis Off J WASOG. 1999;16(2):149–73.

  13. Wells AU, Desai SR, Rubens MB, Goh NSL, Cramer D, Nicholson AG, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med [Internet]. 2003;167(7):962–9.

    Article  Google Scholar 

  14. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med [Internet]. 2015;373(8):782–782.

  15. Walsh SLF, Calandriello L, Sverzellati N, Wells AU, Hansell DM. Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT. Thorax [Internet]. 2016;71(1):45–51.

    Article  Google Scholar 

  16. Van Der Vis JJ, Snetselaar R, Kazemier KM, Ten Klooster L, Grutters JC, Van Moorsel CHM. Effect of Muc5b promoter polymorphism on disease predisposition and survival in idiopathic interstitial pneumonias. Respirology [Internet]. 2016;21(4):712–7.

    Article  Google Scholar 

  17. Abehsera M, Valeyre D, Grenier P, Jaillet H, Battesti JP, Brauner MW. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. Am J Roentgenol. 2000;174(6):1751–7.

    CAS  Article  Google Scholar 

  18. Baughman RP, Shlobin OA, Wells AU, Alhamad EH, Culver DA, Barney J, et al. Clinical features of sarcoidosis associated pulmonary hypertension: results of a multi-national registry. Respir Med [Internet]. 2018;139:72–8.

    Article  Google Scholar 

  19. Chan C, Ryerson CJ, Dunne JV, Wilcox PG. Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study. BMC Pulm Med [Internet]. 2019;19(1).

  20. Kampstra NA, van der Nat PB, Dijksman LM, van Beek FT, Culver DA, Baughman RP, et al. Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes. ERJ Open Res [Internet]. 2019;5(4):00094–2019.

    PubMed  PubMed Central  Google Scholar 

  21. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.

    Article  Google Scholar 

  22. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.

    Article  Google Scholar 

  23. Faverio P, Piluso M, De Giacomi F, Della Zoppa M, Cassandro R, Harari S, et al. Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers. Respiration [Internet]. 2020;99(10):838–45.

    CAS  Article  Google Scholar 

  24. Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J [Internet]. 2020;56(2):1902279.

    Article  Google Scholar 

  25. Lederer DJ, Arcasoy SM, Wilt JS, D’Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med [Internet]. 2006;174(6):659–64.

    Article  Google Scholar 

  26. Loveman E, Copley VR, Colquitt JL, Scott DA, Clegg AJ, Jones J, et al. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol [Internet]. 2014;15(1).

  27. Gangemi AJ, Myers CN, Zheng M, Brown J, Butler-LeBair M, Cordova F, et al. Mortality for sarcoidosis patients on the transplant wait list in the Lung Allocation Score era: experience from a high volume center. Respir Med [Internet]. 2019;157:69–76.

    Article  Google Scholar 

  28. Juge P-A, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med [Internet]. 2018;379(23):2209–19.

    CAS  Article  Google Scholar 

  29. Stock CJ, Sato H, Fonseca C, Banya WAS, Molyneaux PL, Adamali H, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax [Internet]. 2013;68(5):436–41.

    Article  Google Scholar 

  30. Tiosano S, Versini M, Dar Antaki L, Spitzer L, Yavne Y, Watad A, et al. The long-term prognostic significance of sarcoidosis-associated pulmonary hypertension—a cohort study. Clin Immunol [Internet]. 2019;199:57–61.

    CAS  Article  Google Scholar 

  31. Handa T, Nagai S, Miki S, Fushimi Y, Ohta K, Mishima M, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest [Internet]. 2006;129(5):1246–52.

    Article  Google Scholar 

  32. Huitema MP, Bakker ALM, Mager JJ, Rensing BJWM, Smits F, Snijder RJ, et al. Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study [Internet]. Eur Respir J. NLM (Medline); 2019; 54.

  33. Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J [Internet]. 2008;32(2):296–302.

    CAS  Article  Google Scholar 

  34. Alhamad EH, Idrees MM, Alanezi MO, Alboukai AA, Shaik SA. Sarcoidosis-associated pulmonary hypertension: clinical features and outcomes in Arab patients. Ann Thorac Med [Internet]. 2010;5(2):86–91.

    Article  Google Scholar 

  35. Milman N, Svendsen CB, Iversen M, Videbæk R, Carlsen J. Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil. Clin Respir J [Internet]. 2009;3(4):207–13.

    CAS  Article  Google Scholar 

  36. Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest [Internet]. 2005;128(3):1483–9.

    Article  Google Scholar 

Download references


We would like to thank Dr van Es for acting as a third thoracic radiologist.


This study is part of the TopZorg Lung Grant funded by ZonMw (no. 842002001).

Author information

Authors and Affiliations



MS: conceptualization, formal analysis, investigation, writing-original draft preparation; DM: reviewing HRCT’s, data interpretation; AV: conceptualization, writing-reviewing and editing, supervision; LL: reviewing HRCT’s; CM: writing-reviewing and editing, supervision; JV: performed genotyping of MUC5B, writing-reviewing and editing; MV: conceptualization, writing-reviewing and editing, supervision, JG: conceptualization, supervision. All authors read and approved the final manuscript.

Corresponding author

Correspondence to M. C. Schimmelpennink.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Medical research Ethics Committees United (MEC-U) of the St. Antonius Hospital (R05-08A) and all subjects gave written informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schimmelpennink, M.C., Meek, D.B., Vorselaars, A.D.M. et al. Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis. Respir Res 23, 169 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • PF-ILD
  • Advanced sarcoidosis
  • Mortality
  • Diffusion capacity